---
title: "GH Research PLC (GHRS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GHRS.US.md"
symbol: "GHRS.US"
name: "GH Research PLC"
industry: "Pharmaceuticals"
datetime: "2026-05-21T01:33:17.107Z"
locales:
  - [en](https://longbridge.com/en/quote/GHRS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GHRS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GHRS.US.md)
---

# GH Research PLC (GHRS.US)

## Company Overview

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company’s lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.ghres.com](https://www.ghres.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -26.68 | 212 | - | - | - |
| PB | 5.72 | 155 | 3.40 | 2.97 | 2.66 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 67% |
| Overweight | 3 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 22.54 |
| Highest Target | 70.00 |
| Lowest Target | 32.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/GHRS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/GHRS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/GHRS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/GHRS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**